Form 4: Select Medical Executive Chairman Granted 250,000 Restricted Shares

Robert A. Ortenzio, Executive Chairman of Select Medical Holdings Corp, was granted 250,000 shares of restricted common stock, vesting over three years.

Summary

• Robert A. Ortenzio, Executive Chairman and Director of Select Medical Holdings Corp (SEM), was granted 250,000 shares of common stock.
• The transaction date for this grant was July 29, 2025.
• The shares were granted at a price of $0, indicating a restricted stock award.
• These restricted shares will vest in equal annual installments over a period of three years.
• Following this transaction, Mr. Ortenzio directly beneficially owns 7,081,788 shares of common stock.
• He also indirectly beneficially owns an additional 2,120,245 shares through various trusts: 1,279,000 shares via the Robert A. Ortenzio Descendants Trust, and 280,415 shares each via three separate 2014 trusts for Bryan A. Ortenzio, Kevin M. Ortenzio, and Madeline G. Ortenzio.
• Mr. Ortenzio disclaims beneficial ownership of the indirectly held securities except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive like the Executive Chairman is generally a positive signal, indicating alignment of interests and a commitment to long-term performance. The future transaction date is unusual but does not inherently change the positive nature of the grant itself.

Positives

• The grant of restricted stock to the Executive Chairman aligns management's interests with long-term shareholder value creation.
• The three-year vesting schedule encourages sustained performance and retention of key leadership.

Future Outlook

The filing indicates a future vesting schedule for the granted restricted stock, with equal annual installments over three years, suggesting a long-term commitment from the executive.

Industry Context

This insider transaction reflects a standard practice in executive compensation within the healthcare services industry, where restricted stock grants are commonly used to incentivize long-term performance and align executive interests with shareholder returns. Such grants are a typical component of a comprehensive executive compensation package aimed at retention and performance.

Related Party Transactions

• Robert A. Ortenzio indirectly holds shares through the Robert A. Ortenzio Descendants Trust and three Robert A. Ortenzio 2014 Trusts for his descendants, which are considered related party holdings.

Stakeholder Impact

• Shareholders: The grant aligns the Executive Chairman's interests with shareholders, potentially leading to improved long-term performance.

Next Steps

• The granted restricted stock will vest in equal annual installments over three years, starting from the transaction date of July 29, 2025.

Key Dates

Recommendation

While the restricted stock grant to the Executive Chairman is a positive signal for management alignment and long-term commitment, a single Form 4 filing primarily reports an insider transaction and does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors, as it indicates stability in executive incentives, but does not present new fundamental data for a strong directional call.

Keywords

Select Medical Holdings Corp, SEM, Robert A. Ortenzio, Restricted Stock Grant, Executive Compensation, Insider Transaction, Form 4, Common Stock, Corporate Governance